Is There an Ethical Obligation to Disclose Controversial Risk? A Question From the ACCORD Trial-Reference-Cited by-同舟云学术

Is There an Ethical Obligation to Disclose Controversial Risk? A Question From the ACCORD Trial

Published:2014-04-03 Issue:4 Volume:14 Page:4-10
ISSN:1526-5161
Container-title:The American Journal of Bioethics
language:en
Short-container-title:The American Journal of Bioethics

Author:

DeMarco Joseph P.,Ford Paul J.,Patton Dana J.,Stewart Douglas O.

Publisher

Informa UK Limited

Subject

Health Policy,Issues, ethics and legal aspects

Link

http://www.tandfonline.com/doi/pdf/10.1080/15265161.2014.889240

Reference25 articles.

1. Cardiovascular Events and Correlates in the Veterans Affairs Diabetes Feasibility Trial

2. The length of consent documents in oncological trials is doubled in twenty years

3. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials

4. Code of Federal Regulations.General requirements for informed consent. Public Welfare: Title 45 Section 46–116. Available at: http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk Assessment of Medical Study Procedures in the Documents Submitted to a Research Ethics Committee;Journal of Empirical Research on Human Research Ethics;2020-02-08

2. A 7.0–7.7% value for glycated haemoglobin is better than a <7% value as an appropriate target for patient-centered drug treatment of type 2 diabetes mellitus;Annals of Translational Medicine;2019-07

3. The Ethical Imperative of Risk Disclosure in Research: The Answer Is Always Yes;The American Journal of Bioethics;2014-04-03

4. Equipoise and Nonmedical Risks;The American Journal of Bioethics;2014-04-03

5. Disclosure of Risks and Uncertainties Are Especially Vital in Light of Regenerative Medicine;The American Journal of Bioethics;2014-04-03